Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Kidney (renal cell) cancer
Stage/Subtype:  stage IV renal cell cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 75 for your search:
Start Over
Pazopanib Hydrochloride in Treating Patients with Metastatic Kidney Cancer Who Have No Evidence of Disease after Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: E2810, NCI-2012-00723, CDR0000730383, ECOG-E2810, NCT01575548
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-214, NCI-2014-01993, 2014-001750-42, NCT02231749
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Stereotactic Radiosurgery in Treating Patients With Kidney Tumors Who are Poor Candidates for Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 12806, NCI-2010-01064, NCT00458484
Entinostat in Combination with Aldesleukin in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 145208, NCI-2012-02900, CDR0000662915, NCI 7870, NCT01043159, RPCI #23, 7870, NCT01038778
Genetically Modified T Cells, Aldesleukin, and Combination Chemotherapy in Treating Patients with Metastatic Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11-C-0013, NCI-2013-01468, 1004-1036, 110013, 344344, P10648, RD-10-IV-02, NCT01218867
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients with Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1153, NCI-2012-00095, CDR0000720022, NCCTG-N1153, NCT01497444
Everolimus and Hydroxychloroquine in Treating Patients With Previously Treated Kidney Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 07811, NCI-2012-00170, NCT01510119
Hydroxychloroquine and Aldesleukin in Treating Patients With Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT11PLK01, NCI-2012-00427, 11-080, 1302010628, NCT01550367
Panobinostat and Everolimus in Treating Patients with Metastatic or Unresectable Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 146308, NCI-2009-01599, NCT01037257, NCT01582009
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 191711, NCI-2012-01247, 13-069, NCT01684397
A Phase 1/2 Study to Evaluate MEDI4736
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI4736-1108, NCI-2012-02062, NCT01693562
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15246, NCI-2014-02649, I4C-MC-JTBF, NCT02082210
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RX-0201-P2-A-09, NCI-2014-02443, NCT02089334
A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CDX1127-04, NCI-2015-00740, NCT02386111
Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLAG525X2101C, NCI-2015-00966, NCT02460224
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed By Donor Bone Marrow Transplant in Treating Patients With Hematologic Malignancy or Kidney Cancer
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Everolimus Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-23409, NCI-2012-00764, 06-08-20-01, NCT00831480
Pentostatin and Cyclophosphamide Followed by Donor Stem Cell Transplant and Donor Lymphocyte Infusions in Treating Patients with Metastatic Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: 08-C-0088, NCI-2009-00299, CDR0000648215, NCT00641485, 8242, NCT00923845
Bevacizumab and Erlotinib Hydrochloride in Treating Patients with Hereditary Leiomyomatosis and Advanced Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-C-0114, NCI-2013-01459, 100114, P10628, NCT01130519
Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer That Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: E1808, NCI-2011-02055, CDR0000681614, ECOG-E1808, NCT01164228
Pazopanib Hydrochloride or Temsirolimus in Treating Patients With Metastatic or Locally Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0358, NCI-2011-01277, NCT01392183
Start Over